Weight Loss Clinic in Knighton
Mounjaro and Wegovy, prescribed by a GPhC-registered Independent Prescriber and dispensed on-site. Two miles from Knighton, free initial consultation.
Real weight loss, prescribed properly — walking distance from Knighton.
Knighton residents have a pharmacist-led weight loss clinic right up Welford Road — Clarendon Pharmacy, two miles north and about seven minutes by car. Free patient parking on-site, and you can practically walk it from the south end of Knighton.
Mounjaro (tirzepatide) and Wegovy (semaglutide) are prescription-only medicines that need a qualified prescriber. The clinic is led by Mohammed Kolia (MPharm, IP), a GPhC-registered Independent Prescriber, which means we can assess, prescribe, dispense and review your treatment all in one place. No relay through a GP, no separate online prescriber sitting in another city.
Treatment starts with a free, no-obligation consultation. We'll check your BMI, run through your medical history, your goals, and confirm whether GLP-1 treatment is clinically appropriate. NICE recommends these medicines for adults with a BMI of 30 or above (or 27.5 if you have a weight-related condition like type 2 diabetes, hypertension, or sleep apnoea).
After your first prescription you'll book back monthly for a check-in — weight, side effects, dose escalation if appropriate, and your next month's supply. Most patients see clear progress within 12–16 weeks. No subscription, no contract — you stop when you're ready.
GLP-1 weight loss treatment for Knighton residents
Knighton sits at the south end of Welford Road, adjacent to the University of Leicester and the affluent LE2 residential corridor. The local demographic skews to professionals, academics, and established families — demographics with high awareness of metabolic health, often coming to GLP-1 treatment with prior knowledge of HbA1c, cholesterol, and the relationship between visceral fat and cardiovascular risk.
Clarendon Pharmacy is two miles north on Welford Road — walkable from the south end of Knighton, about seven minutes by car. Mohammed Kolia (MPharm, IP) is a GPhC-registered Independent Prescriber, which means assessment, prescription, dispensing and monthly reviews all happen in one place.
NICE eligibility criteria
NICE recommends GLP-1 weight-management treatment for adults who meet specific BMI thresholds:
| BMI | Eligibility |
|---|---|
| 30 or above | Eligible (general population) |
| 27.5–29.9 | Eligible IF you have a weight-related condition (type 2 diabetes, hypertension, sleep apnoea, NAFLD, dyslipidaemia) |
| Below 27.5 | Not recommended — risks outweigh benefits |
For South Asian, Black African and Black Caribbean populations, NICE recommends adjusted lower BMI thresholds (27.5 instead of 30) because cardiovascular risk emerges at lower BMI.
Pairing GLP-1 with metabolic bloods
Many Knighton patients come to us already wanting baseline bloods (HbA1c, lipid panel, liver function, kidney function, thyroid, vitamin D) before starting GLP-1 treatment. This is good clinical practice — it gives an objective starting point and reveals any underlying issues that might affect treatment. We can run the full baseline panel during the same consultation, with UKAS-accredited lab results in 24–48 hours, then start treatment a few days later once results are reviewed.
At 6 months, repeat bloods quantify the metabolic improvements GLP-1 treatment typically produces — reductions in HbA1c often exceed 10mmol/mol, total cholesterol typically drops 0.5–1.5 mmol/L, ALT (liver enzyme) reductions are common in patients with NAFLD.
How do Mounjaro and Wegovy work?
Both mimic GLP-1, a hormone naturally released after eating that signals fullness and slows stomach emptying. Mounjaro additionally acts on GIP, making it a dual GLP-1/GIP agonist. Effects: feel full sooner on smaller meals, hungry less often between meals, reduced food cravings (especially high-calorie/high-reward foods), prolonged satiety.
Mounjaro vs Wegovy
In head-to-head trials, Mounjaro tends to produce greater average weight loss — SURMOUNT-1 showed 21% reduction at full dose vs Wegovy's 15% in STEP-1. Individual response varies. Some patients respond better to Wegovy, or tolerate it better. Independent prescribing means we can switch you if one isn't working.
What to expect month-by-month
Weeks 1–4: modest appetite reduction, possible mild nausea, 1–3kg loss. Weeks 5–8: appetite suppression more pronounced, early side effects settling, weight loss accelerates. Months 3–6: dose escalates to maintenance, 5–12% body weight loss typical. Months 6–12: 15–20% total weight loss common.
Side effects: the full picture
Most common (>10%): nausea, indigestion, constipation or diarrhoea, weeks 1–8. Less common: gallbladder problems; pancreatitis (rare); thyroid effects (contraindicated in medullary thyroid cancer history or MEN-2). Full prescribing data at the eMC SmPC for Mounjaro KwikPen.
Lifestyle and the maintenance question
GLP-1 treatment is most effective when paired with lifestyle change. Strength training preserves muscle mass during weight loss; protein-forward eating supports satiety; structured eating windows help avoid grazing on appetite-suppressed days. The maintenance question is genuine — trials show ~two-thirds weight regain within a year of stopping unless behavioural changes are embedded. Use GLP-1 as a window to build habits that survive without it; taper rather than stopping abruptly.
How much does treatment cost?
Pricing varies by dose. We charge for medication only — initial consultation, monthly reviews, injection demonstration, and prescription itself are included. No subscription, no auto-billing, no contract.
Getting to Welford Road from Knighton
Two miles north on Welford Road, straight up the road. About seven minutes by car; 25-minute walk from south Knighton. Free patient parking on-site. The 84, 85 and 31 buses run regularly. Cyclists have dedicated infrastructure on the Welford Road route. For monthly review appointments (10–15 minutes each), this proximity means a total time commitment of around 30 minutes including travel — sustainable for a year-long programme.
What's included in your weight loss programme.
Free initial consultation, GLP-1 prescription on-site by an Independent Prescriber, monthly progress reviews. No subscription, no contract.
Free initial consultation
Mounjaro (tirzepatide)
Wegovy (semaglutide)
Independent Prescriber on-site
Monthly progress reviews
Stop anytime
Three steps from consultation to first injection.
Free consultation, prescription, monthly reviews. Stop anytime.
Free initial consultation
Prescription and first injection
Monthly reviews and dose escalation
Two miles from Knighton. Free patient parking.
Walk-in welcome Monday to Saturday. Same-day bookings available most of the time.
Two minutes north on Welford Road — Knighton is right by the clinic.
- Mon09:00 – 19:00
- Tue09:00 – 19:00
- Wed09:00 – 19:00
- Thu09:00 – 19:00
- Fri09:00 – 19:00
- Sat09:00 – 17:00
- SunClosed
Common questions about Mounjaro and Wegovy.
If your question isn't here, give us a call and we'll talk it through.
References for this page
Every clinical claim above is sourced from an authoritative public reference.
- 01NICE TA1026NICETirzepatide for managing overweight and obesityhttps://www.nice.org.uk/guidance/ta1026Accessed 12 May 2026
- 02NICE TA875NICESemaglutide for managing overweight and obesityhttps://www.nice.org.uk/guidance/ta875Accessed 12 May 2026
- 03MHRA Drug Safety UpdateMHRAGLP-1 receptor agonists — prescribing and safety informationhttps://www.gov.uk/drug-safety-updateAccessed 12 May 2026
- 04Electronic Medicines Compendium (eMC)MHRAMounjaro KwikPen Summary of Product Characteristicshttps://www.medicines.org.uk/emc/product/14149Accessed 12 May 2026
- 05NHSNHSObesity overview and treatment optionshttps://www.nhs.uk/conditions/obesity/Accessed 12 May 2026
- 06General Pharmaceutical CouncilGPHCRegister entry — Mohammed Kolia (Reg. 2073260)https://www.pharmacyregulation.org/registers/pharmacist/2073260Accessed 12 May 2026
Information on this page is for general guidance. Suitability for GLP-1 weight loss treatment depends on BMI, medical history, and clinical assessment. A consultation determines whether treatment is appropriate.
